NewAmsterdam Pharma (NASDAQ:NAMS) is Frazier Life Sciences Management L.P.'s Largest Position

Frazier Life Sciences Management L.P. boosted its stake in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 23.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 15,916,418 shares of the company's stock after buying an additional 3,061,224 shares during the period. NewAmsterdam Pharma makes up about 17.0% of Frazier Life Sciences Management L.P.'s investment portfolio, making the stock its largest holding. Frazier Life Sciences Management L.P. owned 17.23% of NewAmsterdam Pharma worth $409,052,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the stock. Deerfield Management Company L.P. Series C grew its holdings in shares of NewAmsterdam Pharma by 378.4% during the fourth quarter. Deerfield Management Company L.P. Series C now owns 4,314,340 shares of the company's stock valued at $110,879,000 after buying an additional 3,412,590 shares during the last quarter. Jennison Associates LLC lifted its position in NewAmsterdam Pharma by 291.9% in the 4th quarter. Jennison Associates LLC now owns 3,998,541 shares of the company's stock valued at $102,763,000 after acquiring an additional 2,978,263 shares in the last quarter. Wellington Management Group LLP boosted its stake in NewAmsterdam Pharma by 2,410.4% during the 4th quarter. Wellington Management Group LLP now owns 2,315,123 shares of the company's stock valued at $59,499,000 after purchasing an additional 2,222,900 shares during the last quarter. Capital International Investors bought a new stake in shares of NewAmsterdam Pharma in the 4th quarter worth $53,007,000. Finally, Alliancebernstein L.P. bought a new stake in shares of NewAmsterdam Pharma in the 4th quarter worth $47,752,000. Hedge funds and other institutional investors own 89.89% of the company's stock.

Analyst Ratings Changes

A number of research analysts have recently issued reports on NAMS shares. UBS Group set a $41.00 price target on NewAmsterdam Pharma in a report on Monday, March 3rd. Royal Bank of Canada restated an "outperform" rating and set a $40.00 target price on shares of NewAmsterdam Pharma in a research note on Friday, January 24th. Wall Street Zen lowered shares of NewAmsterdam Pharma from a "hold" rating to a "sell" rating in a research note on Thursday. Needham & Company LLC decreased their price objective on shares of NewAmsterdam Pharma from $42.00 to $40.00 and set a "buy" rating for the company in a report on Thursday, May 8th. Finally, Scotiabank increased their price objective on shares of NewAmsterdam Pharma from $47.00 to $52.00 and gave the company a "sector outperform" rating in a research report on Thursday, February 27th. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat.com, NewAmsterdam Pharma has an average rating of "Moderate Buy" and a consensus target price of $43.00.

Insider Buying and Selling at NewAmsterdam Pharma

In related news, CAO Louise Frederika Kooij sold 150,000 shares of NewAmsterdam Pharma stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $20.37, for a total transaction of $3,055,500.00. Following the transaction, the chief accounting officer now directly owns 15,000 shares in the company, valued at approximately $305,550. The trade was a 90.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director James N. Topper purchased 1,135 shares of NewAmsterdam Pharma stock in a transaction on Wednesday, March 26th. The stock was bought at an average price of $22.49 per share, with a total value of $25,526.15. Following the transaction, the director now owns 3,013,569 shares of the company's stock, valued at approximately $67,775,166.81. This represents a 0.04% increase in their ownership of the stock. The disclosure for this purchase can be found here. 20.84% of the stock is owned by corporate insiders.

NewAmsterdam Pharma Price Performance

NewAmsterdam Pharma stock traded down $0.67 during mid-day trading on Friday, reaching $17.61. 274,673 shares of the stock traded hands, compared to its average volume of 637,089. The stock has a market capitalization of $1.93 billion, a PE ratio of -9.37 and a beta of 0.01. The business's 50-day moving average is $18.58 and its 200-day moving average is $21.24. NewAmsterdam Pharma has a 12-month low of $14.06 and a 12-month high of $27.29.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.45) by ($0.04). The firm had revenue of $2.98 million for the quarter, compared to analysts' expectations of $1.46 million. Equities analysts anticipate that NewAmsterdam Pharma will post -1.75 EPS for the current fiscal year.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.